Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab in Pretreated Metastatic EGFR-Positive Colorectal Cancer
NCT00079066Phase 3Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Dec 2003
- Primary completion
- Nov 2006
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of cetuximab in colorectal cancer (CRC) (2 arms), sponsored by Canadian Cancer Trials Group. Primary endpoint: Overall Survival. Started Dec 2003; status: completed.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00079066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00079066.